Recombinant Tuberculosis BCG Vaccine Elicits a Highly Protective Host Immune Response
- Technology Benefits
- Directs a hosts immune response towards a more potent protective immune response. More efficacious than the currently available vaccine and even rBCG30, which itself is more potent than the currently available vaccine.
- Technology Application
- A more potent and effective vaccine against TB.
- Detailed Technology Description
- UCLA researchers have developed an improved version of the rBCG30 vaccine that co-expresses host immunostimulatory molecules that shift the hosts immune response towards a more protective type of immune response. These vaccines are significantly more potent than the first generation rBCG30 vaccine in the highly relevant and stringent outbred guinea pig model of pulmonary tuberculosis, a model that closely mimics human tuberculosis.
- Supplementary Information
- Patent Number: US8287879B2
Application Number: US2008296666A
Inventor: Horwitz, Marcus A. | Harth, Gunter
Priority Date: 16 Oct 2003
Priority Number: US8287879B2
Application Date: 9 Oct 2008
Publication Date: 16 Oct 2012
IPC Current: A61K003902 | A61K003904 | A61K004500 | A61K004700
US Class: 4242001 | 4242341 | 4242481 | 4242781
Assignee Applicant: The Regents of the University of California
Title: Immunostimulatory recombinant intracellular pathogen immunogenic compositions and methods of use
Usefulness: Immunostimulatory recombinant intracellular pathogen immunogenic compositions and methods of use
Summary: The immunogenic composition comprising a recombinant Bacille Calmette Guerin (rBCG) expressing at least one Mycobacteria major extracellular protein is useful as vaccine against pathogenic bacteria, e.g., Mycobacterium bovis .
Novelty: New immunogenic composition comprising a recombinant Bacille Calmette Guerin (rBCG) expressing at least one Mycobacteria major extracellular protein, useful as vaccine against pathogenic bacteria, e.g., Mycobacterium bovis
- Industry
- Biomedical
- Sub Category
- Pathogen
- Application No.
- 8287879
- Others
-
State of Development
This vaccine has been tested and proven effective in guinea pigs.
Background
The only currently available TB vaccine, an attenuated Mycobacterium bovis strain Bacille Calmette-Guerin (BCG), is of variable efficacy. A large carefully conducted meta-analysis has estimated the potency of BCG to be approximately 50%. UCLA researchers developed and reported in the last several years a recombinant BCG expressing the Mycobacterium tuberculosis 30 kDa major secretory protein (r30). This vaccine, named rBCG30, induces greater protection than BCG against aerosol challenge with a highly virulent strain of M. tuberculosis.
Additional Technologies by these Inventors
- New Recombinant Tuberculosis BCG Vaccine for Immunocompromised Patients and Others
- Method of Producing Novel Unmarked Recombinant Vaccine Vector for Tuberculosis
- Safe and Potent Vaccines against Tularemia
- Novel Vaccines Against Tularemia
- Improved Immunization Strategy Using Recombinant BCG Vaccines
- Novel Live Recombinant Booster Vaccine against Tuberculosis
- Live Recombinant Tuberculosis Vaccine
Tech ID/UC Case
20146/2006-538-0
Related Cases
2006-538-0
- *Abstract
-
UCLA researchers specializing in infectious diseases have developed an improved method for producing a recombinant tuberculosis (TB) vaccine that elicits a highly potent protective immune response in the host for preventing or treating TB in humans and in animals.
- *IP Issue Date
- Oct 16, 2012
- *Principal Investigator
-
Name: Guenter Harth
Department:
Name: Marcus Horwitz
Department:
Name: Michael Tullius
Department:
- Country/Region
- USA
